Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089986 · ClinicalTrials.gov registry record · Phase 2
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,415
- Enrollment target
NCT00089986 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,415 participants.
The verdict
NCT00089986, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,415 participants
- Enrollment target
Study Summary
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis. GR270773 will be administered as a three-day continuous intravenous infusion.
Interventions
- OTHER Placebo
- DRUG Intravenous GR270773- Phospholipid Emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2004-09-01 |
| Est. Completion | 2007-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089986
The ClinicalTrials.gov registry entry for NCT00089986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00089986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089986 about?
NCT00089986 is a clinical study titled "GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults". The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis. GR270773 will be administered as a three-day continuous intravenous infusio...
What is the current status of trial NCT00089986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,415 participants. The study started on 2004-09-01. Estimated completion is 2007-04-15.
What interventions are being tested in trial NCT00089986?
The interventions under investigation include: Placebo (OTHER), Intravenous GR270773- Phospholipid Emulsion (DRUG).
Who is sponsoring clinical trial NCT00089986?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.